PSP Research LLC
13F Reported Value
ⓘ$187.9M
Holdings
75
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
PSP Research LLC disclosed 75 positions worth $187.9M in its Form 13F-HR for Q2 2026. During the quarter the fund opened 11 new positions and exited 15 and a full exit from $SERA. The portfolio is most concentrated in Other (85.7% of disclosed assets). All figures are sourced directly from PSP Research LLC’s Form 13F-HR filing with the SEC under CIK 2106939.
Sector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
SPDR SERIES TRUST - ST STR SP BIOT
—Quality
$90.2M570,000 shISHARES TR - 0-3 MTH TREASURY
—Quality
$70.5M700,000 sh- —
Quality
$616.8K11,000 sh - 13.2
Quality
$606.5K25,000 sh - 81.2
Quality
$600.8K5,300 sh - —
Quality
$594.7K641 sh - —
Quality
$585.1K8,000 sh - —
Quality
$583.4K14,000 sh - 31.0
Quality
$567.6K17,000 sh - —
Quality
$559.5K30,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| SPDR SERIES TRUST - ST STR SP BIOT | — | $90.2M | 570,000 |
| ISHARES TR - 0-3 MTH TREASURY | — | $70.5M | 700,000 |
 Royalty Pharma plc$RPRX | — | $616.8K | 11,000 |
 Nurix Therapeutics, Inc.$NRIX | 13.2 | $606.5K | 25,000 |
 INCYTE CORP$INCY | 81.2 | $600.8K | 5,300 |
 ARGENX SE$ARGX | — | $594.7K | 641 |
 Disc Medicine, Inc.$IRON | — | $585.1K | 8,000 |
 Rapport Therapeutics, Inc.$RAPP | — | $583.4K | 14,000 |
 Ultragenyx Pharmaceutical Inc.$RARE | 31.0 | $567.6K | 17,000 |
 Trevi Therapeutics, Inc.$TRVI | — | $559.5K | 30,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of PSP Research LLC's 75 positions.
Showing top 10 of 75 holdings.
Sector Allocation
Other
$161.1M
Healthcare
$26.7M
Technology
$143,000
Full Holdings — PSP Research LLC (Q2 2026)
All 75 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | — | SPDR SERIES TRUST - ST STR SP BIOT | $90.2M | 48.0% | +100% | — |
| 2 | — | ISHARES TR - 0-3 MTH TREASURY | $70.5M | 37.5% | +0% | — |
| 3 | $RPRX | Royalty Pharma plc | $616,770 | 0.3% | +0% | — |
| 4 | $NRIX | Nurix Therapeutics, Inc. | $606,500 | 0.3% | -13% | 13.2 |
| 5 | $INCY | INCYTE CORP | $600,808 | 0.3% | +0% | 81.2 |
| 6 | $ARGX | ARGENX SE | $594,701 | 0.3% | +0% | — |
| 7 | $IRON | Disc Medicine, Inc. | $585,120 | 0.3% | +0% | — |
| 8 | $RAPP | Rapport Therapeutics, Inc. | $583,380 | 0.3% | +0% | — |
| 9 | $RARE | Ultragenyx Pharmaceutical Inc. | $567,630 | 0.3% | -23% | 31 |
| 10 | $TRVI | Trevi Therapeutics, Inc. | $559,500 | 0.3% | +0% | — |
| 11 |  $GLUE | Monte Rosa Therapeutics, Inc. | $556,600 | 0.3% | -18% | 18.1 |
| 12 |  $TGTX | TG THERAPEUTICS, INC. | $549,400 | 0.3% | -23% | 68.4 |
| 13 |  $HALO | HALOZYME THERAPEUTICS, INC. | $547,890 | 0.3% | -13% | 81.2 |
| 14 |  $IONS | IONIS PHARMACEUTICALS INC | $539,172 | 0.3% | +0% | 37.1 |
| 15 |  $PHVS | Pharvaris N.V. | $518,700 | 0.3% | -25% | — |
| 16 |  $ARQT | Arcutis Biotherapeutics, Inc. | $516,534 | 0.3% | +0% | 41.2 |
| 17 |  $AUPH | Aurinia Pharmaceuticals Inc. | $509,100 | 0.3% | +0% | 73.3 |
| 18 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $505,605 | 0.3% | -22% | 75.4 |
| 19 |  $IMVT | Immunovant, Inc. | $500,890 | 0.3% | -32% | — |
| 20 |  $ACAD | ACADIA PHARMACEUTICALS INC | $500,080 | 0.3% | +0% | 69.8 |
| 21 |  $PTCT | PTC THERAPEUTICS, INC. | $489,420 | 0.3% | +0% | 80 |
| 22 |  $CLDX | Celldex Therapeutics, Inc. | $483,730 | 0.3% | +0% | 13.2 |
| 23 |  $IMCR | Immunocore Holdings plc | $480,727 | 0.3% | +0% | — |
| 24 |  $DFTX | Definium Therapeutics, Inc. | $470,400 | 0.3% | -71% | — |
| 25 |  $COGT | Cogent Biosciences, Inc. | $464,400 | 0.3% | +0% | — |
| 26 |  $KYMR | Kymera Therapeutics, Inc. | $458,680 | 0.2% | -37% | 29.2 |
| 27 |  $DYN | Dyne Therapeutics, Inc. | $444,200 | 0.2% | +0% | — |
| 28 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $441,009 | 0.2% | +0% | 60.9 |
| 29 |  $TARS | Tarsus Pharmaceuticals, Inc. | $440,580 | 0.2% | +0% | 40.8 |
| 30 |  $SNDX | Syndax Pharmaceuticals Inc | $437,200 | 0.2% | +0% | 30 |
| 31 |  $EXEL | EXELIXIS, INC. | $435,280 | 0.2% | -33% | 79.4 |
| 32 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $411,620 | 0.2% | +0% | 26.5 |
| 33 |  $NAMS | NewAmsterdam Pharma Co N.V. | $406,680 | 0.2% | -20% | — |
| 34 | — | ASCENDIS PHARMA A/S - ORD SHS | $400,080 | 0.2% | NEW | — |
| 35 |  $LQDA | Liquidia Corp | $398,650 | 0.2% | NEW | 37.4 |
| 36 |  $STOK | Stoke Therapeutics, Inc. | $392,640 | 0.2% | +0% | 53.4 |
| 37 |  $VKTX | Viking Therapeutics, Inc. | $390,100 | 0.2% | -33% | — |
| 38 |  $IMNM | Immunome Inc. | $381,420 | 0.2% | -10% | 5.8 |
| 39 |  $PTGX | Protagonist Therapeutics, Inc | $367,740 | 0.2% | +0% | 24.8 |
| 40 |  $HRMY | Harmony Biosciences Holdings, Inc. | $364,100 | 0.2% | -30% | 75.3 |
| 41 |  $ELVN | Enliven Therapeutics, Inc. | $355,250 | 0.2% | +0% | — |
| 42 |  $SYRE | Spyre Therapeutics, Inc. | $355,120 | 0.2% | -22% | — |
| 43 |  $NTLA | Intellia Therapeutics, Inc. | $338,400 | 0.2% | -26% | 24.5 |
| 44 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $322,170 | 0.2% | +0% | 25.4 |
| 45 |  $KNSA | Kiniksa Pharmaceuticals International, plc | $319,750 | 0.2% | -44% | — |
| 46 |  $ALKS | Alkermes plc. | $314,370 | 0.2% | +0% | — |
| 47 |  $TNGX | Tango Therapeutics, Inc. | $312,600 | 0.2% | -31% | 26.9 |
| 48 |  $ARDX | ARDELYX, INC. | $306,000 | 0.2% | -25% | 35.3 |
| 49 |  $VERA | Vera Therapeutics, Inc. | $300,370 | 0.2% | -30% | — |
| 50 |  $MIRM | Mirum Pharmaceuticals, Inc. | $292,675 | 0.2% | -50% | 32.7 |
| 51 |  $ORKA | Oruka Therapeutics, Inc. | $285,510 | 0.1% | -40% | — |
| 52 |  $SUPN | SUPERNUS PHARMACEUTICALS, INC. | $279,060 | 0.1% | +0% | 45.3 |
| 53 |  $CRSP | CRISPR Therapeutics AG | $272,700 | 0.1% | -47% | 4.5 |
| 54 |  $ZYME | Zymeworks Inc. | $261,400 | 0.1% | +0% | 27.2 |
| 55 |  $KRYS | Krystal Biotech, Inc. | $257,196 | 0.1% | NEW | 75.9 |
| 56 |  $CMPS | COMPASS Pathways plc | $254,700 | 0.1% | -75% | — |
| 57 |  $XENE | Xenon Pharmaceuticals Inc. | $253,512 | 0.1% | +0% | 12.9 |
| 58 |  $AXSM | Axsome Therapeutics, Inc. | $244,770 | 0.1% | -65% | 36.6 |
| 59 |  $AVBP | ArriVent BioPharma, Inc. | $244,604 | 0.1% | NEW | — |
| 60 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $243,700 | 0.1% | -50% | 26.8 |
| 61 |  $JAZZ | Jazz Pharmaceuticals plc | $233,982 | 0.1% | NEW | — |
| 62 |  $KOD | Kodiak Sciences Inc. | $233,760 | 0.1% | -40% | — |
| 63 |  $RVMD | Revolution Medicines, Inc. | $224,736 | 0.1% | NEW | — |
| 64 |  $BBIO | BridgeBio Pharma, Inc. | $223,440 | 0.1% | -50% | 31.7 |
| 65 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $222,060 | 0.1% | NEW | 30.3 |
| 66 |  $DNLI | Denali Therapeutics Inc. | $217,668 | 0.1% | NEW | — |
| 67 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $211,926 | 0.1% | NEW | 74.4 |
| 68 |  $SRRK | Scholar Rock Holding Corp | $210,485 | 0.1% | NEW | — |
| 69 |  $EWTX | Edgewise Therapeutics, Inc. | $203,150 | 0.1% | -23% | — |
| 70 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $194,650 | 0.1% | +0% | — |
| 71 |  $CTMX | CytomX Therapeutics, Inc. | $147,750 | 0.1% | NEW | 19.1 |
| 72 |  $OCUL | OCULAR THERAPEUTIX, INC | $147,300 | 0.1% | +0% | 12.8 |
| 73 |  $EYPT | EyePoint, Inc. | $143,000 | 0.1% | +0% | 10.3 |
| 74 |  $ORIC | Oric Pharmaceuticals, Inc. | $140,790 | 0.1% | +0% | — |
| 75 |  $OLMA | Olema Pharmaceuticals, Inc. | $125,100 | 0.1% | +0% | — |
New Positions (11)
$LQDA Liquidia Corp$398,650$KRYS Krystal Biotech, Inc.$257,196$AVBP ArriVent BioPharma, Inc.$244,604$JAZZ Jazz Pharmaceuticals plc$233,982$RVMD Revolution Medicines, Inc.$224,736$RYTM RHYTHM PHARMACEUTICALS, INC.$222,060$DNLI Denali Therapeutics Inc.$217,668$ARWR ARROWHEAD PHARMACEUTICALS, INC.$211,926$SRRK Scholar Rock Holding Corp$210,485$CTMX CytomX Therapeutics, Inc.$147,750Exited Positions (15)
$SERA SERA PROGNOSTICS, INC.
$TYRA Tyra Biosciences, Inc.
$ASND Ascendis Pharma A/S
$CYTK CYTOKINETICS INC
$AGIO AGIOS PHARMACEUTICALS, INC.
$PRAX Praxis Precision Medicines, Inc.
$INBX Inhibrx Biosciences, Inc.
$ERAS Erasca, Inc.
$CELC Celcuity Inc.
$KALV KalVista Pharmaceuticals, Inc.
$LEGN Legend Biotech Corp
$APGE Apogee Therapeutics, Inc.
$UTHR UNITED THERAPEUTICS Corp
$SMMT Summit Therapeutics Inc.
$CMPX Compass Therapeutics, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for PSP Research LLC including:
Track PSP Research LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for PSP Research LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: PSP Research LLC
13F Pro is an AI hedge fund tracker and stock research platform. For PSP Research LLC (SEC CIK: 2106939), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in PSP Research LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.